Entera Bio Ltd. SG&A Expenses

SG&A Expenses of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending June 29, 2020 was $1.54 Million (a 19.15% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 43.24%
  • Annual SG&A Expenses for 2019 was $4.28 Million (a 50.58% increase from previous year)
  • Annual SG&A Expenses for 2018 was $2.84 Million (a -66.85% decrease from previous year)
  • Twelve month SG&A Expenses ending June 29, 2020 was $5.42 Million (a 20.13% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 47.15% year-over-year
Trailing SG&A Expenses for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$5.42 Million $4.52 Million $4.28 Million $3.69 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of Entera Bio Ltd.

Most recent SG&A Expensesof ENTX including historical data for past 10 years.

Interactive Chart of SG&A Expenses of Entera Bio Ltd.

Entera Bio Ltd. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $1.54 $1.29
2019 $1.52 $1.07 $0.63 $1.06 $4.28
2018 $0.93 $1.06 $-0.41 $1.26 $2.84
2017 $8.58

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.